5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial.

Pérez-García JM, Cortés J, Ruiz-Borrego M, Stradella A, Bermejo B, Escrivá-de-Romaní S, Reboredo C, Albacar C, Martínez-Jáñez N, Iranzo V, Ribelles N, Dalenc F, Prat A, Schmid P, Gebhart G, Marmé F, Di Cosimo S, Braga S, Colleoni M, Antonarelli G, Notini G, Gion M, García-Mosquera JJ, Sanz L, Martinez-Garcia E, Meya A, Dustin D, Amaya-Garrido A, Guerrero-Martínez JA, Alcalá-López D, Rodríguez-Morató J, Mina L, Mancino M, Llombart-Cussac A

Open source

DOI: 10.1038/s41591-026-04723-w
Published: 2026 Oct 29
Container: Nature medicine
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41591-026-04723-w,
  title = {5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial.},
  author = {Pérez-García JM and Cortés J and Ruiz-Borrego M and Stradella A and Bermejo B and Escrivá-de-Romaní S and Reboredo C and Albacar C and Martínez-Jáñez N and Iranzo V and Ribelles N and Dalenc F and Prat A and Schmid P and Gebhart G and Marmé F and Di Cosimo S and Braga S and Colleoni M and Antonarelli G and Notini G and Gion M and García-Mosquera JJ and Sanz L and Martinez-Garcia E and Meya A and Dustin D and Amaya-Garrido A and Guerrero-Martínez JA and Alcalá-López D and Rodríguez-Morató J and Mina L and Mancino M and Llombart-Cussac A},
  year = {2026},
  journal = {Nature medicine},
  doi = {10.1038/s41591-026-04723-w},
  url = {https://doi.org/10.1038/s41591-026-04723-w}
}

RIS

TY  - JOUR
TI  - 5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial.
AU  - Pérez-García JM
AU  - Cortés J
AU  - Ruiz-Borrego M
AU  - Stradella A
AU  - Bermejo B
AU  - Escrivá-de-Romaní S
AU  - Reboredo C
AU  - Albacar C
AU  - Martínez-Jáñez N
AU  - Iranzo V
AU  - Ribelles N
AU  - Dalenc F
AU  - Prat A
AU  - Schmid P
AU  - Gebhart G
AU  - Marmé F
AU  - Di Cosimo S
AU  - Braga S
AU  - Colleoni M
AU  - Antonarelli G
AU  - Notini G
AU  - Gion M
AU  - García-Mosquera JJ
AU  - Sanz L
AU  - Martinez-Garcia E
AU  - Meya A
AU  - Dustin D
AU  - Amaya-Garrido A
AU  - Guerrero-Martínez JA
AU  - Alcalá-López D
AU  - Rodríguez-Morató J
AU  - Mina L
AU  - Mancino M
AU  - Llombart-Cussac A
PY  - 2026
JO  - Nature medicine
DO  - 10.1038/s41591-026-04723-w
UR  - https://doi.org/10.1038/s41591-026-04723-w
ER  -

APA

JM, P., J, C., M, R., A, S., B, B., S, E., C, R., C, A., N, M., V, I., N, R., F, D., A, P., P, S., G, G., F, M., S, D. C., S, B., M, C., G, A., G, N., M, G., JJ, G., L, S., E, M., A, M., D, D., A, A., JA, G., D, A., J, R., L, M., M, M., & A, L. (2026). 5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial.. Nature medicine. https://doi.org/10.1038/s41591-026-04723-w

Source records

pubmed · retrieved 2026-11-10T12:32:37.697Z